Is the active ingredient.
Treatment of pulmonary arterial hypertension (PAH) in patients classified as WHO Functional Class II or III.
Specifically, it's used to improve exercise capacity and delay clinical worsening in PAH patients.
Zambri 5mg Tablet (Ambrisentan) is an endothelin receptor antagonist. It selectively blocks the binding of endothelin-1 to its ETA receptors. Endothelin-1 is a potent vasoconstrictor, and by blocking its action, ambrisentan helps to relax and widen blood vessels in the lungs, improving blood flow and reducing pulmonary vascular resistance.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F). Protect from light and moisture. Keep out of reach of children.
The recommended starting dose is typically 5 mg once daily.
The dose may be increased to 10 mg once daily based on individual patient response and tolerability.
It's crucial to follow your doctor's prescribed dosage and administration instructions precisely.
Headache
Peripheral edema (swelling in the extremities)
Nasal congestion
Dizziness
Upper respiratory tract infection
Fatigue
Syncope (fainting)
The interaction between ambrisentan and alcohol is not fully characterized; consult your doctor.
Ambrisentan may cause dizziness or syncope. Avoid driving or operating machinery until you know how it affects you.
Ambrisentan is contraindicated in pregnancy. It's unknown if ambrisentan is excreted in breast milk; breastfeeding is not recommended while taking this medication.
Safety and effectiveness in pediatric patients have not been established.
Dosage adjustments may be necessary in patients with severe kidney impairment. Consult your doctor.
Ambrisentan is metabolized by the liver. Regular monitoring of liver enzymes is essential. Dosage adjustments or discontinuation may be needed for patients with liver dysfunction.
Please consult your physician or pharmacist for detailed information and specific prescribing information.
Refer to the official drug monograph for complete details.
